NCT01563718View on ClinicalTrials.gov

Pre-Release VIVITROL for Opioid Dependent Inmates

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Substance-Related Disorders
Interventions
DRUG

naltrexone for extended release injectable suspension

VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.

Trial Locations (1)

02903

Rhode Island Hospital, Providence

Sponsors

Collaborators (1)

Alkermes, Inc.
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Alkermes, Inc.

INDUSTRY

lead

Rhode Island Hospital

OTHER